Post by a pharmacist or physician (I believe), taken from investors hub, which was taken from Yahoo.
I have not seen this previously, but more indication that the collective analysis of the evidence here is not misplaced:
"From Yahoo by Michael:
"My job is to inform our providers of the best treatment options for our patients. I work closely with our infectious disease specialist and discuss covid related topics on a regular basis. Our clinical pharmacy team has been following the progress of leronlimab and several other therapies hoping to see approval soon so that we can reduce morbidity and mortality. Not only that, but working in the front lines makes us hope that there are good options for our own protection when and if the time comes to be treated ourselves.
Our clinical pharmacy team has done a great deal of research looking at the role of cytokines and chemokines in the progression of mild to moderate disease into full blown ARDS. The inhibition of CCL5 at the CCR5 receptor and its effects on chemotaxis and reducing the comorbidities of RANTES makes the most sense to us; we have tried to find holes in Dr Patterson's papers and lectures but have found none.
The GM CSF inhibitor Lenzilumab also looks interesting but in one of Dr Patterson's lectures he states that in his workups GM CSF is only elevated in about 25% of patients. This could wind up going the way of the IL-6 inhibitors where there was a great deal of excitement initially only to find that inhibition of the sole cytokine had minimal results. Compassionate use showed good results but time will tell if further studies back up the claims by Humanigen.
The CD6 ALCAM inhibitor Itolizumab is also intriguing. It's mechanism affects several cytokines including IL-6 and TNF alpha. There was a small study in India that showed very promising results. A larger phase 3 trial should be launched in the next couple weeks to see if there is good efficacy in ARDS. Results of this trial should be seen sometime in Q4.
Remestemcel-L is also quite promising and is in a phase 2/3 trial to treat Covid related ARDS. Mesoblast says that they are capable of mass producing stem cell therapy post trials and the therapy was very promising in compassionate use. The problem I see is that this therapy requires IV administration done in a clinical setting and should be cost prohibitive but if it comes to saving lives it might be worth it. Obviously, the advantage of leronlimab is abdominal subcutaneous administration that the patient could self-administer thus being considerably cheaper.
Leronlimab is ahead of the game however. Cytodyn should post Mild to Moderate Phase 2 trial results any day. I have little doubt given the exceptional safety data that efficacy should be solid; even if it shows great improvement in only one area such as D Dimer it would be a huge victory. Given the mechanism, I feel that there should be multiple areas of significant improvement vs the placebo group. Odds are pretty small that leronlimab will show no benefit over placebo across the board. "
Every time I have a doubt, I interrogate my friend, who is an emergency medicine, about what I am missing and where there are holes in Dr. Patterson's manuscript and analysis.
Neither of us have been able to identify a flaw in his methodology or conclusions.
I remain flabbergasted that the writing has been on the wall for 10 weeks and so few see it or care.
Many will be kicking themselves when the larger medical and investment communities wake up.
I have not seen this previously, but more indication that the collective analysis of the evidence here is not misplaced:
"From Yahoo by Michael:
"My job is to inform our providers of the best treatment options for our patients. I work closely with our infectious disease specialist and discuss covid related topics on a regular basis. Our clinical pharmacy team has been following the progress of leronlimab and several other therapies hoping to see approval soon so that we can reduce morbidity and mortality. Not only that, but working in the front lines makes us hope that there are good options for our own protection when and if the time comes to be treated ourselves.
Our clinical pharmacy team has done a great deal of research looking at the role of cytokines and chemokines in the progression of mild to moderate disease into full blown ARDS. The inhibition of CCL5 at the CCR5 receptor and its effects on chemotaxis and reducing the comorbidities of RANTES makes the most sense to us; we have tried to find holes in Dr Patterson's papers and lectures but have found none.
The GM CSF inhibitor Lenzilumab also looks interesting but in one of Dr Patterson's lectures he states that in his workups GM CSF is only elevated in about 25% of patients. This could wind up going the way of the IL-6 inhibitors where there was a great deal of excitement initially only to find that inhibition of the sole cytokine had minimal results. Compassionate use showed good results but time will tell if further studies back up the claims by Humanigen.
The CD6 ALCAM inhibitor Itolizumab is also intriguing. It's mechanism affects several cytokines including IL-6 and TNF alpha. There was a small study in India that showed very promising results. A larger phase 3 trial should be launched in the next couple weeks to see if there is good efficacy in ARDS. Results of this trial should be seen sometime in Q4.
Remestemcel-L is also quite promising and is in a phase 2/3 trial to treat Covid related ARDS. Mesoblast says that they are capable of mass producing stem cell therapy post trials and the therapy was very promising in compassionate use. The problem I see is that this therapy requires IV administration done in a clinical setting and should be cost prohibitive but if it comes to saving lives it might be worth it. Obviously, the advantage of leronlimab is abdominal subcutaneous administration that the patient could self-administer thus being considerably cheaper.
Leronlimab is ahead of the game however. Cytodyn should post Mild to Moderate Phase 2 trial results any day. I have little doubt given the exceptional safety data that efficacy should be solid; even if it shows great improvement in only one area such as D Dimer it would be a huge victory. Given the mechanism, I feel that there should be multiple areas of significant improvement vs the placebo group. Odds are pretty small that leronlimab will show no benefit over placebo across the board. "
Every time I have a doubt, I interrogate my friend, who is an emergency medicine, about what I am missing and where there are holes in Dr. Patterson's manuscript and analysis.
Neither of us have been able to identify a flaw in his methodology or conclusions.
I remain flabbergasted that the writing has been on the wall for 10 weeks and so few see it or care.
Many will be kicking themselves when the larger medical and investment communities wake up.
19
